1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6E43E5FB8C3BD138D852576B300360EFD
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/new-product-planning-role-and-activities-for-medical-marketing?opendocument
18
19opendocument
20107.23.176.162
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services

Pharmaceutical New Product Planning: Role and Activities for Medical Affairs

ID: PSM-249


Features:

10 Info Graphics

8 Data Graphics

131 Metrics

33 Narratives


Pages: 50


Published: Pre-2013


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

Buy this research as part of a

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • VIEW TOC AND LIST OF EXHIBITS
Leading pharmaceutical and biotech companies are increasingly under pressure to deliver effective new products in shorter time frames while minimizing development costs.The structure, activities, and resources of New Product Planning (NPP) groups are critical to focusing new product development and optimizing product portfolios.

Best Practices LLC's benchmarking study examines the role and impact of NPP groups on product commercialization efforts in pharmaceutical and biotech companies. It provides reliable benchmarks, observations, and best practice insights to inform and shape executive thinking around the challenges of new product development in
medical affairs.

Industries Profiled:
Pharmaceutical; Biotech; Consumer Products; Diagnostic; Health Care


Companies Profiled:
Abbott Laboratories; Sanofi-aventis; Actelion; Alcon; Astellas; Allergan; Auxilium; Almirall; Theravance; Altus Biologics; Victory; Amgen; Bayer Healthcare; Biogen Idec; Daiichi Pharmaceutical Co.; Ltd.; Eli Lilly; EMD Serono; Human Genome Sciences; Merck; Novartis; Ortho Biotech; Stiefel; Takeda Pharmaceuticals; UCB Pharma


Study Snapshot

Research was conducted through survey and interviews of 27 New Product Planning leaders from 25 different companies across the globe contributed data. Additionally, In-depth interviews were conducted with leaders from 13 of the participating companies.
Key Topics Include:
  • Assess current state of New Product Planning in pharma
  • Provide overview of New Product Planning activities and timing during development process
  • Review the main Medical Affairs activities carried out during the development process and drill down on their timing, intended outcomes, and value for the organization
Table of Contents

RESEARCH BACKGROUND 3
Benchmark Class and Segmentation 6
Participant Information 8

NEW PRODUCT PLANNING 11
Commercial Insights 13
Coping With Industry Challenges 16

NEW PRODUCT PLANNING ACTIVITIES 17
Key Findings 18
New Product Planning and Development Activity 19

NEW PRODUCT PLANNING ACTIVITIES: MEDICAL MARKETING 22
Key Findings and Activities 23
Global New Product Planning 26
Regional New Product Planning 28
Advisory Boards 29
Identifying and Managing KOLs 31
Medical Meeting Planning 35
Publication Strategy 38
Advisory Boards Insight 39
Branding of the Science Insight 40
KOL Management Insight 41
Publication Insight 45

ABOUT BEST PRACTICES 49

List of Charts & Exhibits

Organizational Demographics
  • Development Phases where Medical Marketing Activities are Conducted